Literature DB >> 33631550

Sex differences in circulating inflammatory mediators as a function of substance use disorder.

April C May1, Kaiping Burrows2, Leandra K Figueroa-Hall2, Namik Kirlic2, Evan J White2, Ryan Smith2, Hamed Ekhtiari2, Martin P Paulus3, Jonathan Savitz3, Jennifer L Stewart3.   

Abstract

BACKGROUND: Substance use disorders (SUD) with comorbid depression and anxiety are linked to poor treatment outcome and relapse. Although some depressed individuals exhibit elevated blood-based inflammation (interleukin-6 [IL-6] and C reactive protein [CRP]), few studies have examined whether the presence of SUD exacerbates inflammation.
METHODS: Treatment-seeking individuals with major depressive disorder (MDD), anxiety disorders, and/or SUD (N = 160; 80 % with MDD) recruited into the Tulsa 1000 study provided blood samples, participated in clinical interviews, and completed a questionnaire battery querying symptoms of current psychopathology and emotional processing. Analyses followed a multistep process. First, groups were created on the presence versus absence of 1+ lifetime SUD diagnoses: SUD+ (37 F, 43 M) and SUD- (60 F, 20 M). Second, a principal component analysis (PCA) of questionnaire data resulted in two factors, one indexing negative emotionality/withdrawal motivation and one measuring positive emotionality/approach motivation. Third, SUD groups, extracted PCA factors, and nuisance covariates (age, body mass index [BMI], nicotine use, psychotropic medication [and hormone/contraception use in females]) were entered as simultaneous predictors of blood-based inflammation (IL-6, IL-8, IL-10, tumor necrosis factor-α, and CRP).
RESULTS: Within females, SUD + exhibited higher IL-8 and IL-10 but lower CRP levels than SUD-. In contrast, SUD was not associated with biomarker levels in males. Across sexes, higher BMI was linked to higher IL-6 and CRP levels, and within the five biomarkers, IL-6 and CRP shared the most variance.
CONCLUSION: These findings point to sex-specific inflammatory profiles as a function of SUD that may provide new targets for intervention.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  C-reactive protein; Chemokines; Cytokines; Depression; Inflammation; Interleukin-10; Interleukin-8; Substance use disorder; Tumor necrosis factor-alpha

Mesh:

Substances:

Year:  2021        PMID: 33631550      PMCID: PMC8026624          DOI: 10.1016/j.drugalcdep.2021.108610

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.852


  79 in total

1.  Plasma cytokine levels in patients with chronic alcohol overconsumption: Relations to gut microbiota markers and clinical correlates.

Authors:  Steinar Traae Bjørkhaug; Sudan Prasad Neupane; Jørgen G Bramness; Håvard Aanes; Viggo Skar; Asle W Medhus; Jørgen Valeur
Journal:  Alcohol       Date:  2019-10-11       Impact factor: 2.405

2.  Replication and reproducibility issues in the relationship between C-reactive protein and depression: A systematic review and focused meta-analysis.

Authors:  Sarah R Horn; Madison M Long; Benjamin W Nelson; Nicholas B Allen; Philip A Fisher; Michelle L Byrne
Journal:  Brain Behav Immun       Date:  2018-06-19       Impact factor: 7.217

3.  Multiple DSM-5 substance use disorders: A national study of US adults.

Authors:  Sean Esteban McCabe; Brady T West; Emily M Jutkiewicz; Carol J Boyd
Journal:  Hum Psychopharmacol       Date:  2017-07-27       Impact factor: 1.672

4.  Innate immune signaling in the ventral tegmental area contributes to drug-primed reinstatement of cocaine seeking.

Authors:  Kyle T Brown; Sophia C Levis; Casey E O'Neill; Alexis L Northcutt; Timothy J Fabisiak; Linda R Watkins; Ryan K Bachtell
Journal:  Brain Behav Immun       Date:  2017-08-13       Impact factor: 7.217

5.  Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS®): depression, anxiety, and anger.

Authors:  Paul A Pilkonis; Seung W Choi; Steven P Reise; Angela M Stover; William T Riley; David Cella
Journal:  Assessment       Date:  2011-06-21

6.  The impact of comorbid anxiety and depression on alcohol treatment outcomes.

Authors:  Lucy Burns; Maree Teesson; Katy O'Neill
Journal:  Addiction       Date:  2005-06       Impact factor: 6.526

7.  Robust dimensions of anxiety sensitivity: development and initial validation of the Anxiety Sensitivity Index-3.

Authors:  Steven Taylor; Michael J Zvolensky; Brian J Cox; Brett Deacon; Richard G Heimberg; Deborah Roth Ledley; Jonathan S Abramowitz; Robert M Holaway; Bonifacio Sandin; Sherry H Stewart; Meredith Coles; Winnie Eng; Erin S Daly; Willem A Arrindell; Martine Bouvard; Samuel Jurado Cardenas
Journal:  Psychol Assess       Date:  2007-06

8.  Impact of comorbid psychiatric disorders on the outcome of substance abusers: a six year prospective follow-up in two Norwegian counties.

Authors:  Anne Signe Landheim; Kjell Bakken; Per Vaglum
Journal:  BMC Psychiatry       Date:  2006-10-20       Impact factor: 3.630

9.  The Multidimensional Assessment of Interoceptive Awareness (MAIA).

Authors:  Wolf E Mehling; Cynthia Price; Jennifer J Daubenmier; Mike Acree; Elizabeth Bartmess; Anita Stewart
Journal:  PLoS One       Date:  2012-11-01       Impact factor: 3.240

10.  Sex Differences in the Peripheral Immune System in Patients with Depression.

Authors:  Badari Birur; Ellen M Amrock; Richard C Shelton; Li Li
Journal:  Front Psychiatry       Date:  2017-06-16       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.